Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 13;8(15):3875-3879.
doi: 10.1182/bloodadvances.2024013212.

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

Esperanza Martín-Sánchez  1 , Laura Blanco  1 , Peter S Kim  2 , Kamlesh Bisht  2 , Hongfang Wang  2 , Helgi Van de Velde  2 , Tomas Jelinek  1   3 , Catia Simoes  1 , Felipe Prosper  1 , Jesus F San Miguel  1 , Ana Alfonso  1 , Juan Bergua  4 , Rebeca Rodríguez-Veiga  5 , Susana Vives  6 , David Martínez-Cuadrón  5 , Pau Montesinos  5 , Bruno Paiva  1 , Aintzane Zabaleta  1
Affiliations

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

Esperanza Martín-Sánchez et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: B.P. reports honoraria for lectures from and membership on advisory boards with Amgen, Bristol Myers Squibb, Celgene, Janssen, Merck, Novartis, Roche, and Sanofi; unrestricted grants from Celgene, EngMab, Sanofi, and Takeda; and consultancy for Celgene, Janssen, Sanofi, and Takeda. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
CD38 expression and tumor immune composition in older patients with AML. (A) Distribution of 241 older patients with newly diagnosed AML according to the pattern of CD38 expression: negative, heterogeneous, and homogeneous positive. (B) OS of the 241 older patients with AML treated in the PETHEMA/FLUGAZA phase 3 clinical trial, stratified according to the percentage of CD38+ tumor cells at diagnosis: <50% (green), 50% to 99% (blue) and 100% (red). (C-D) CD38 expression in patient-matched tumor cells at diagnosis, complete response after 3 induction cycles in patients with measurable residual disease (MRD, n = 10), and at relapse (n = 3). (E) Mean fluorescence intensity (MFI) of CD38 in tumor cells from the 241 patients with AML and in BM plasma cells from 10 healthy adults. (F) t-Distributed Stochastic Neighbor Embedding (t-SNE) projection nucleated cells in the BM of older patients with AML and healthy adults (n = 10). (G-H) Frequency of BM NK and T lymphocytes among total alive nucleated cells in BM from patients with AML vs healthy adults. All panels, ∗P < .05; ns, non-significant.
Figure 2.
Figure 2.
Targeting CD38 with isatuximab and a CD38/CD3 × CD28 trispecific T-cell engager (CD38-TCE). The KG-1 as well as the MOLM-13 and OCI-AML3 AML cell lines were selected because of their respective low and bright density of CD38. (A) Triplicates of antibody-dependent cellular cytotoxicity (ADCC) were performed after 24 hours of treatment with isatuximab (70 nM) in coculture with NK lymphocytes from healthy adults (1:1 effector to target cell [E:T] ratio). ADCC was measured as the percentage of annexin-V+ tumor cells. (B) Triplicates of antibody-dependent cellular phagocytosis (ADCP) in coculture with monocyte-derived macrophages obtained from healthy adults (1:2 Φ:AML cell ratio) were performed after labeling with violet proliferation dye (VPD) and pretreatment with isatuximab (70 nM) for 30 minutes. ADCP was measured as the percentage of CD14/CD300e/VPD triple-positive macrophages after 2 hours of coculture. (C) Tumor depletion in BM aspirates from older patients with AML (n = 17) after treatment with isatuximab (70 nM) during 24 hours. Results are represented as the relative increment observed in treated vs untreated samples. (D) Using the Infinicyt software (Cytognos, Salamanca, Spain), we merged the fetal calf serum files of blasts from older patients with AML (n = 241) with those from KG-1, MOLM-13 and OCI-AML3 cell lines. The mean fluorescence intensity (MFI) of CD38 (measured with the clone HB7 conjugated with APCH7; BD Biosciences, San Jose, CA) is represented by population-band histograms, and ordered from the lowest into the highest expression detected among AML cell lines. The MFI of CD38 required to trigger ADCC and ADCP induced by isatuximab is represented by a hypothetical vertical dash line for a schematic representation of the results described in panels A-B. (E) MOLM-13 cells were labeled with VPD, pretreated with isatuximab or the CD38-TCE and their respective isotypes for 30 minutes, and cocultured with PBMC from healthy adults (n = 6) in a 10:1 E:T ratio. After 48 hours, the activation of effector cells was measured according to the percentage of CD69+ T and NK lymphocytes. For statistical significance, the highest dose was compared with the isotype-treated condition: green and blue symbols represent T and NK cells, respectively; ∗ and # indicated treatment with isatuximab and the CD38-TCE, respectively. (F) Tumor cell death of MOLM-13 induced by pretreatment with isatuximab and the CD38-TCE was determined using annexin V staining after 24 and 48 hours of coculture in the presence of PBMC from healthy adults. (G) Tumor cell death in primary samples from patients with AML (n = 8) after treatment with isatuximab (700 pM) and the CD38-TCE (700 pM) for 48 hours. The percentage of tumor cell death was calculated as follows: [(% leukemic cells in untreated – % of leukemic cells in treated sample)/% of leukemic cells in untreated] × 100. Each colored line is a patient sample, and the 2 cases having tumor cells resistant to isatuximab while being sensitive to the CD38-TCE are represented by the pink and gray lines. (H) After 48 hours of treatment with the CD38-TCE (700 pM), the percentages of neutrophils, monocytes, NK, B, as well as CD4 and CD8 T lymphocytes among CD45+ nucleated cells in BM were normalized to those observed upon treatment with the isotype, which was set up to 100%. In all panels, 1 symbol (∗ or #), P < .05; 2 symbols, P < .01; 3 symbols, P < .001.
See this image and copyright information in PMC

References

    1. Juliusson G, Antunovic P, Derolf Å, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry. Blood. 2009;113(18):4179–4187. - PubMed
    1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152. - PubMed
    1. DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135(2):85–96. - PubMed
    1. Ossenkoppele G, Löwenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125(5):767–774. - PubMed
    1. Thol F, Döhner H, Ganser A. How I treat refractory and relapsed acute myeloid leukemia. Blood. 2024;143(1):11–20. - PubMed

Publication types